NCT00002314已完成2 期
A Phase II Study of Oral Ro 24-7429 (Tat Antagonist) in Patients With HIV-Related Kaposi's Sarcoma
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 试验地点
- 4
研究概览
简要总结
To study the effects of Ro 24-7429 on tumor growth in patients with HIV-related Kaposi's sarcoma. To study the safety and tolerance, effects on HIV replication, and immunologic effects of Ro 24-7429 in this patient population. To explore relationships between exposure to Ro 24-7429 and its metabolites with its antitumor and antiviral activities and drug toxicity.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
研究点 (4)
Loading locations...
相似试验
终止
1 期
PTC299 in Treating Patients With HIV-Related Kaposi SarcomaKaposi's SarcomaNCT00686842AIDS Malignancy Consortium17
已完成
2 期
The Safety and Effectiveness of Ritonavir in the Treatment of HIV-Related Kaposi's SarcomaSarcoma, KaposiHIV InfectionsNCT00002366Abbott
已完成
2 期
Treatment of Classical Non-HIV-Related Kaposi's Sarcoma With the Antiviral Drug IndinavirClassical Kaposi's SarcomaNCT00362310Istituto Superiore di Sanità28
已完成
4 期
HIV/AIDS Kaposis Sarcoma: Comparison of Response to HAART vs HAART Plus CXTKaposi's SarcomaHIVAIDSHuman Herpesvirus 8NCT00380770University of KwaZulu112
已完成
1 期
A Dose-Escalating Study of Ro 31-8959 ( HIV Protease Inhibitor ) in Patients With HIV Disease.HIV InfectionsNCT00002111Stanford University32